In Vitro Model of the Cystic Fibrosis Bronchial Epithelium Via iPS Technology (PaCyFIC)
Status
Conditions
Study type
Funder types
Identifiers
Details and patient eligibility
About
In order to further enable physiopathology studies, the aim of this project is to validate an in vitro model of cystic fibrosis created using induced pluripotent stemcell (iPS) differentiated bronchial epithelium from cystic fibrosis (CF) patients homozygous for the p.Phe508del mutation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Full description
The investigator's primary objective is to generate iPS lines from 3 CF patients and from 3 healthy subjects.
Secondary objectives include verification that cell lines express the CFTR gene according to their genotype, verification or relative production of the CFTR protein for each iPS line, and amplification of obtain iPS lines for aliquot creation to facilitate sharing.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for subjects with Cystic Fibrosis:
- Homozygote for the p.Phe508del mutation
- Signed informed consent given by the subject
Inclusion Criteria for subjects without Cystic Fibrosis:
- Signed informed consent given by the subject
Exclusion Criteria:
- Pregnancy, breastfeeding
- Participant in an exclusion period determined by a previous study
- Participant under any kind of guardianship
- Unaffiliated with or not a beneficiary of a social security program (health insurance)
- Subject deprived of liberty (e.g. prisoners)
- Subject with positive infectious markers for HIV1, HIV2, HBC or HBV
Exclusion Criteria for subjects with Cystic Fibrosis:
- Any pathology requiring a treatment or a pathology not requiring treatment but with clinical significance according to the investigator
Trial design
6 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal